GI
ACRV icon

GAMMA Investing’s Acrivon Therapeutics ACRV Stock Holding History

GAMMA Investing’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-287
Closed -$583 – 3774
2025
Q1 		$583 Buy
287
+253
+744% +$1.36K ﹤0.01% 3653
2024
Q4 		$205 Buy
+34
New +$247 ﹤0.01% 3702

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

GAMMA Investing's ACRV Position: Q2 2025 in Review

GAMMA Investing sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 287 shares — an estimated $583 sold.

GAMMA Investing first reported a position in ACRV in Q4 2024 and held it in 2 quarters. The position peaked at $583 in Q1 2025. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

  • GAMMA Investing reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GAMMA Investing sold 287 Acrivon Therapeutics shares in Q2 2025, an estimated $583.
  • GAMMA Investing first reported a position in Acrivon Therapeutics in Q4 2024 and held it in 2 quarters.
  • GAMMA Investing's Acrivon Therapeutics position peaked at $583 in Q1 2025.
  • 53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on GAMMA Investing's 13F filing for Q2 2025, filed 14 Jul 2025.